These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 38551727)
1. Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay. Hashimoto T; Nakamura Y; Oki E; Kobayashi S; Yuda J; Shibuki T; Bando H; Yoshino T Int J Clin Oncol; 2024 May; 29(5):495-511. PubMed ID: 38551727 [TBL] [Abstract][Full Text] [Related]
2. Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA). Chin RI; Chen K; Usmani A; Chua C; Harris PK; Binkley MS; Azad TD; Dudley JC; Chaudhuri AA Mol Diagn Ther; 2019 Jun; 23(3):311-331. PubMed ID: 30941670 [TBL] [Abstract][Full Text] [Related]
3. Harnessing Minimal Residual Disease as a Predictor for Colorectal Cancer: Promising Horizons Amidst Challenges. Wen X; Coradduzza D; Shen J; Scanu AM; Muroni MR; Massidda M; Rallo V; Carru C; Angius A; De Miglio MR Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893604 [TBL] [Abstract][Full Text] [Related]
4. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection. Abbosh C; Birkbak NJ; Swanton C Nat Rev Clin Oncol; 2018 Sep; 15(9):577-586. PubMed ID: 29968853 [TBL] [Abstract][Full Text] [Related]
5. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis. Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376 [TBL] [Abstract][Full Text] [Related]
6. Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments. Oh Y; Yoon SM; Lee J; Park JH; Lee S; Hong T; Chung LI; Sudhaman S; Riddell T; Palsuledesai CC; Krainock M; Liu MC; Chae YK Thorac Cancer; 2024 May; 15(13):1095-1102. PubMed ID: 38558374 [TBL] [Abstract][Full Text] [Related]
7. Molecular Residual Disease-guided Adjuvant Treatment in Resected Colorectal Cancer: Focus on CIRCULATE-Japan. Sato S; Nakamura Y; Oki E; Yoshino T Clin Colorectal Cancer; 2023 Mar; 22(1):53-58. PubMed ID: 36567192 [TBL] [Abstract][Full Text] [Related]
8. Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer. Ryoo SB; Heo S; Lim Y; Lee W; Cho SH; Ahn J; Kang JK; Kim SY; Kim HP; Bang D; Kang SB; Yu CS; Oh ST; Park JW; Jeong SY; Kim YJ; Park KJ; Han SW; Kim TY Br J Cancer; 2023 Aug; 129(2):374-381. PubMed ID: 37280413 [TBL] [Abstract][Full Text] [Related]
9. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases. Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868 [No Abstract] [Full Text] [Related]
10. Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection. Lonardi S; Nimeiri H; Xu C; Zollinger DR; Madison RW; Fine AD; Gjoerup O; Rasola C; Angerilli V; Sharma S; Wu HT; Palsuledesai CC; Malhotra M; Aleshin A; Loupakis F; Renkonen E; Hegde P; Fassan M Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232827 [TBL] [Abstract][Full Text] [Related]
11. CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Taniguchi H; Nakamura Y; Kotani D; Yukami H; Mishima S; Sawada K; Shirasu H; Ebi H; Yamanaka T; Aleshin A; Billings PR; Rabinowitz M; Oki E; Takemasa I; Kato T; Mori M; Yoshino T Cancer Sci; 2021 Jul; 112(7):2915-2920. PubMed ID: 33931919 [TBL] [Abstract][Full Text] [Related]
12. ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine. Pellini B; Pejovic N; Feng W; Earland N; Harris PK; Usmani A; Szymanski JJ; Qaium F; Mudd J; Petty M; Jiang Y; Singh A; Maher CA; Henke LE; Park H; Ciorba MA; Kim H; Mutch MG; Pedersen KS; Tan BR; Hawkins WG; Fields RC; Chaudhuri AA JCO Precis Oncol; 2021; 5():. PubMed ID: 34250420 [TBL] [Abstract][Full Text] [Related]
13. Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review). Chen H; Zhou Q Oncol Rep; 2023 May; 49(5):. PubMed ID: 37052271 [TBL] [Abstract][Full Text] [Related]
14. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer. Arisi MF; Dotan E; Fernandez SV Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457259 [TBL] [Abstract][Full Text] [Related]
15. Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices. Malla M; Loree JM; Kasi PM; Parikh AR J Clin Oncol; 2022 Aug; 40(24):2846-2857. PubMed ID: 35839443 [TBL] [Abstract][Full Text] [Related]
16. Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease. Moding EJ; Nabet BY; Alizadeh AA; Diehn M Cancer Discov; 2021 Dec; 11(12):2968-2986. PubMed ID: 34785539 [TBL] [Abstract][Full Text] [Related]
17. Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases. Loupakis F; Sharma S; Derouazi M; Murgioni S; Biason P; Rizzato MD; Rasola C; Renner D; Shchegrova S; Koyen Malashevich A; Malhotra M; Sethi H; Zimmermann BG; Aleshin A; Moshkevich S; Billings PR; Sedgwick JD; Schirripa M; Munari G; Cillo U; Pilati P; Dei Tos AP; Zagonel V; Lonardi S; Fassan M JCO Precis Oncol; 2021 Jul; 5():. PubMed ID: 34327297 [TBL] [Abstract][Full Text] [Related]
18. Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1). Xia L; Mei J; Kang R; Deng S; Chen Y; Yang Y; Feng G; Deng Y; Gan F; Lin Y; Pu Q; Ma L; Lin F; Yuan Y; Hu Y; Guo C; Liao H; Liu C; Zhu Y; Wang W; Liu Z; Xu Y; Li K; Li C; Li Q; He J; Chen W; Zhang X; Kou Y; Wang Y; Wu Z; Che G; Chen L; Liu L Clin Cancer Res; 2022 Aug; 28(15):3308-3317. PubMed ID: 34844976 [TBL] [Abstract][Full Text] [Related]
19. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801 [TBL] [Abstract][Full Text] [Related]
20. Monitoring of gastrointestinal carcinoma via molecular residual disease with circulating tumor DNA using a tumor-informed assay. Qi Z; Li Y; Wang Z; Tan X; Zhou Y; Li Z; Zhao W; Zheng X; Yao J; Li F; Wang W; Wang Z; Pang F; Wang G; Gu W Cancer Med; 2023 Aug; 12(16):16687-16696. PubMed ID: 37602656 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]